Sino Biopharmaceutical (OTCMKTS:SBMFF) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft began coverage on shares of Sino Biopharmaceutical (OTCMKTS:SBMFF – Get Rating) in a report released on Tuesday, The Fly reports. The firm issued a buy rating on the stock.

Sino Biopharmaceutical Stock Performance

Sino Biopharmaceutical stock opened at $0.56 on Tuesday. Sino Biopharmaceutical has a 12 month low of $0.46 and a 12 month high of $0.89. The business’s 50 day simple moving average is $0.56 and its 200 day simple moving average is $0.59.

About Sino Biopharmaceutical

(Get Rating)

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections.